DC Vaccination for Post-remission Therapy in AML
NCT02405338
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
20
Enrollment
INDUSTRY
Sponsor class
Conditions
Acute Myeloid Leukemia
Interventions
BIOLOGICAL:
WT1/PRAME vaccination
Sponsor
Medigene AG